Bevespi Aerosphere is a drug owned by Astrazeneca Pharmaceuticals Lp. It is protected by 7 US drug patents filed from 2016 to 2020 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 17, 2031. Details of Bevespi Aerosphere's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8815258 | Compositions, methods and systems for respiratory delivery of two or more active agents |
Mar, 2031
(6 years from now) | Active |
| US10716753 | Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(5 years from now) | Active |
| US9415009 | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(5 years from now) | Active |
| US8324266 | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(5 years from now) | Active |
| US8808713 | Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(5 years from now) | Active |
| US9463161 | Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems |
May, 2030
(5 years from now) | Active |
| US8703806 | Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents |
May, 2030
(5 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Bevespi Aerosphere's patents.
Latest Legal Activities on Bevespi Aerosphere's Patents
Given below is the list of recent legal activities going on the following patents of Bevespi Aerosphere.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 May, 2024 | US8324266 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 27 Mar, 2024 | US9463161 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 31 Jan, 2024 | US9415009 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 03 Jan, 2024 | US10716753 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Feb, 2022 | US8815258 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 02 Feb, 2022 | US8808713 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Oct, 2021 | US8703806 |
| Post Issue Communication - Certificate of Correction | 09 Dec, 2020 | US10716753 |
| Mail Pub Notice re 312 amendment | 29 Oct, 2020 | US10716753 |
| Email Notification Critical | 29 Oct, 2020 | US10716753 |
FDA has granted several exclusivities to Bevespi Aerosphere. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Bevespi Aerosphere, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Bevespi Aerosphere.
Exclusivity Information
Bevespi Aerosphere holds 1 exclusivities. All of its exclusivities have expired in 2019. Details of Bevespi Aerosphere's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 25, 2019 |
US patents provide insights into the exclusivity only within the United States, but Bevespi Aerosphere is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Bevespi Aerosphere's family patents as well as insights into ongoing legal events on those patents.
Bevespi Aerosphere's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Bevespi Aerosphere's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Mar 17, 2031 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Bevespi Aerosphere Generics:
There are no approved generic versions for Bevespi Aerosphere as of now.
Alternative Brands for Bevespi Aerosphere
Bevespi Aerosphere which is used for the maintenance treatment of chronic obstructive pulmonary disease (COPD)., has several other brand drugs in the same treatment category and using the same active ingredient (Formoterol Fumarate; Glycopyrrolate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Astrazeneca Ab |
| |||
About Bevespi Aerosphere
Bevespi Aerosphere is a drug owned by Astrazeneca Pharmaceuticals Lp. It is used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Bevespi Aerosphere uses Formoterol Fumarate; Glycopyrrolate as an active ingredient. Bevespi Aerosphere was launched by Astrazeneca in 2016.
Approval Date:
Bevespi Aerosphere was approved by FDA for market use on 25 April, 2016.
Active Ingredient:
Bevespi Aerosphere uses Formoterol Fumarate; Glycopyrrolate as the active ingredient. Check out other Drugs and Companies using Formoterol Fumarate; Glycopyrrolate ingredient
Treatment:
Bevespi Aerosphere is used for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
Dosage:
Bevespi Aerosphere is available in aerosol, metered form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.0048MG/INH;0.0090MG/INH | AEROSOL, METERED | Prescription | INHALATION |